ELOX - Company ID 0001035354
The table below shows Eloxx Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$6.33M | -$4.71M | -$14.34M | -$31.84M | -$35.00M | -$28.17M |
| Capital expenditure | - | - | - | $66.00K | $89.00K | - |
| Investing cash flow | $1.00K | $38.00K | $309.00K | -$66.00K | $2.06M | $33.79M |
| Dividends paid | - | - | - | - | - |
Eloxx Pharmaceuticals, Inc. reported operating cash flow of -$6.33M for fiscal year 2025. That is down 34.2% from -$4.71M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$8.84M (FY 2016) to -$6.33M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $11.00M | $3.44M | -$4.08M | $8.81M | $50.79M | -$3.44M |